Zenas Biopharma stock price target raised by Morgan Stanley on MS drug data
PositiveFinancial Markets

Morgan Stanley has raised the stock price target for Zenas Biopharma following promising data on its multiple sclerosis drug. This is significant as it reflects growing confidence in the company's potential to address a major health issue, which could lead to increased investment and support for further development.
— Curated by the World Pulse Now AI Editorial System











